A Novel Interaction Between HER2/neu and Cyclin E in Breast Cancer

HER2/neu (HER2) and cyclin E are important prognostic indicators in breast cancer. As both are involved in cell cycle regulation we analyzed whether there was a direct interaction between the two. HER2 and cyclin E expression levels were determined in 395 breast cancer patients. Patients with HER2-overexpression and high levels of cyclin E had decreased 5-year disease-specific survival compared with low levels of cyclin E (14% versus 89%, P<0.0001). In vitro studies were performed in which HER2-mediated activity in HER2-overexpressing breast cancer cell lines was downregulated by transfection with HER2 small interfering RNA or treatment with trastuzumab. Cyclin E expression levels were determined by western blot analysis, and functional effects analyzed using kinase assays, MTT assays were used to assess cell viability as a marker of proliferation and fluorescence-activated cell sorting analysis was used to determine cell cycle profiles. Decreased HER2-mediated signaling resulted in decreased expression of cyclin E, particularly the low molecular weight (LMW) isoforms. Decreased HER2 and LMW cyclin E expression had functional consequences, including decreased cyclin E-associated kinase activity and decreased proliferation, because of increased apoptosis and an increased accumulation of cells in the G1 phase. In vivo studies performed in a HER2-overexpressing breast cancer xenograft model confirmed the effects of trastuzumab on cyclin E expression. Given the relationship between HER2 and cyclin E, in vitro clonogenic assays were performed to assess combination therapy targeting both proteins. Isobologram analysis showed a synergistic interaction between the two agents (trastuzumab targeting HER2 and roscovitine targeting cyclin E). Taken together, these studies show that HER2-mediated signaling effects LMW cyclin E expression, which in turn deregulates the cell cycle. LMW cyclin E has prognostic and predictive roles in HER2-overexpressing breast cancer, warranting further study of its potential as a therapeutic target.

[1]  James M. Roberts,et al.  Human cyclin E, a nuclear protein essential for the G1-to-S phase transition , 1995, Molecular and cellular biology.

[2]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[3]  S. Reed,et al.  Deregulated cyclin E induces chromosome instability , 1999, Nature.

[4]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[5]  Mollianne J. McGahren,et al.  Tumor-Specific Proteolytic Processing of Cyclin E Generates Hyperactive Lower-Molecular-Weight Forms , 2001, Molecular and Cellular Biology.

[6]  M. Hung,et al.  Overexpression of ErbB2 in cancer and ErbB2-targeting strategies , 2000, Oncogene.

[7]  John F Timms,et al.  Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells , 2002, Oncogene.

[8]  S. Reed,et al.  Altered regulation of G1 cyclins in senescent human diploid fibroblasts: accumulation of inactive cyclin E-Cdk2 and cyclin D1-Cdk2 complexes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[9]  S. Tucker,et al.  Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. , 2007, Cancer research.

[10]  James M. Roberts,et al.  Cyclin-dependent regulation of G1 in mammalian fibroblasts. , 1993, Science.

[11]  K. Keyomarsi,et al.  Cyclin E and Its Low Molecular Weight Forms in Human Cancer and as Targets for Cancer Therapy , 2003, Cancer biology & therapy.

[12]  M. Hung,et al.  Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells , 2001, Nature Cell Biology.

[13]  G. Mills,et al.  Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells. , 1992, Cancer research.

[14]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  K. Keyomarsi,et al.  Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53 , 1998, Oncogene.

[16]  G Brockhoff,et al.  Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK‐BR‐3 breast cancer cell proliferation , 2007, Cell proliferation.

[17]  K. Keyomarsi,et al.  The role of cyclin E in cell proliferation, development and cancer. , 1997, Progress in cell cycle research.

[18]  Y. Yarden,et al.  Cyclin D1 Is Required for Transformation by Activated Neu and Is Induced through an E2F-Dependent Signaling Pathway , 2000, Molecular and Cellular Biology.

[19]  J. Drebin,et al.  Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu. , 2000, Cancer research.

[20]  V. Hu.  The Cell Cycle , 1994, GWUMC Department of Biochemistry Annual Spring Symposia.

[21]  G. Mills,et al.  Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. , 2008, Cancer research.

[22]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Dulic,et al.  老化ヒト二倍体線維芽細胞におけるG1サイクリン調節の変化 不活性サイクリンE‐Cdk2及びサイクリンD1‐Cdk2複合体 , 1993 .

[24]  M. Hung,et al.  Oncogenic Signals of HER-2/neu in Regulating the Stability of the Cyclin-dependent Kinase Inhibitor p27* , 2000, The Journal of Biological Chemistry.

[25]  A. Bednarek,et al.  Cyclin E expression in breast cancer correlates with negative steroid receptor status, HER2 expression, tumor grade and proliferation. , 2006, Journal of experimental & clinical cancer research : CR.

[26]  B. Gusterson,et al.  Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Isabelle Bedrosian,et al.  Cyclin E and survival in patients with breast cancer. , 2002, The New England journal of medicine.

[28]  J. A. Hamilton,et al.  Expression and amplification of cyclin genes in human breast cancer. , 1993, Oncogene.

[29]  E. Lees,et al.  Cyclin E, a potential prognostic marker for breast cancer. , 1994, Cancer research.

[30]  K. Keyomarsi,et al.  Redundant cyclin overexpression and gene amplification in breast cancer cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[31]  K. Keyomarsi,et al.  Anti-HER2 Antibody Trastuzumab Inhibits CDK2-Mediated NPAT and Histone H4 Expression via PI3K Pathway , 2006, Cell cycle.

[32]  K. Keyomarsi,et al.  Processing of cyclin E differs between normal and tumor breast cells. , 2000, Cancer research.

[33]  B Angus,et al.  Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. , 1989, Cancer research.

[34]  S. Tucker,et al.  Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. , 2004, Cancer research.

[35]  W. Gullick,et al.  Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. , 1991, Cancer research.

[36]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[37]  C. Arteaga,et al.  Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. , 2002, Cancer research.

[38]  J. Drebin,et al.  Down-Regulation of HER 2 / neu Expression Induces Apoptosis in Human Cancer Cells That Overexpress HER 2 / neu 1 , 2000 .

[39]  J. Harper,et al.  The Tumor-specific Hyperactive Forms of Cyclin E Are Resistant to Inhibition by p21 and p27* , 2005, Journal of Biological Chemistry.